ALTME.PA TME Pharma N.V.

Healthcare Biotechnology Euronext Paris
0.1072 EUR
Close of Nov 7, 2026
0.0490 0.1746
Market cap
EUR 10.4M
P/E
-
P/B
6.15x
ROE
-
Dividend yield
-
Fundamental score
1.0/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is ALTME.PA undervalued?

Graham number

The Graham number of TME Pharma N.V. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

TME Pharma N.V. fundamental analysis

2 of 11 checks passed

ROE 0/2

The stock's ROE indicates a negative return (-933.21%) on shareholders' equity, suggesting poor financial performance.

ROA 0/2

The stock's ROA (-288.94%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

PBV 2/2

The stock's low PBV ratio (0x) suggests it's undervalued, making it an attractive opportunity for investors.

DER 2/2

The stock has a minimal amount of debt (-321%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

Revenue Growth 0/2

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

Net Profit Growth 0/2

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

Assets Growth 0/2

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

Graham Number 0/1

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

Dividend Growth 0/2

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

Dividend 0/2

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

Buffet Intrinsic Value 0/1

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

TME Pharma N.V. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About TME Pharma N.V.

TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company's Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is mid-stage clinical development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, and glioblastoma. It al…

Full company profile